Company news

Starpharma Holdings Limited news in 2026

Starpharma Holdings Limited's news releases, calls and decks from 2026, newest first.

View company

Chair and Deputy Chair Appointments

November 5, 2026

Results of 2026 Annual General Meeting

November 5, 2026

AGM Chair address and CEO presentation

November 5, 2026

Becoming a substantial holder

November 2, 2026

Application for quotation of securities - SPL

October 29, 2026

Application for quotation of securities - SPL

October 29, 2026

Details of Company Address

October 23, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 21, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 21, 2026

$3.5 Million R&D Tax Incentive Received

October 21, 2026

Starpharma Investor Presentation Petalion Webinar

October 20, 2026

Starpharma secures majority ownership of Petalion

October 19, 2026

Starpharma secures majority ownership of Petalion

October 19, 2026

Trading Halt

October 15, 2026

Change in substantial holding

October 7, 2026

Notice of Annual General Meeting/Proxy Form

October 5, 2026

Change of Director's Interest Notice - C Maley

October 4, 2026

Application for quotation of securities - SPL

October 4, 2026

Notification of cessation of securities - SPL

October 4, 2026

Chair and Deputy Chair Appointments

September 30, 2026

Ceasing to be a substantial holder

September 25, 2026

Becoming a substantial holder

September 22, 2026

Ceasing to be a substantial holder

September 15, 2026

Annual General Meeting 2026 Date

September 15, 2026

Becoming a substantial holder

September 11, 2026

S&P DJI Announces September 2026 Quarterly Rebalance

September 4, 2026

Ceasing to be a substantial holder

August 31, 2026

FY26 Key Financial Results and Annual Report

August 25, 2026

2026 Appendix 4G and Corporate Governance Statement

August 25, 2026

2026 Annual Report

August 25, 2026

Preliminary Final Report

August 25, 2026

Becoming a substantial holder

August 24, 2026

Ceasing to be a substantial holder

August 19, 2026

Change in substantial holding

August 18, 2026

Change in substantial holding

August 13, 2026

Change of Director Interest Notice - R Basser

August 12, 2026

Change of Director Interest Notice - R Thomas

August 12, 2026

Change of Director Interest Notice - L Cheng

August 12, 2026

Change of Director Interest Notice - J Davies

August 12, 2026

Change of Director Interest Notice - C Maley

August 12, 2026

Becoming a substantial holder

August 11, 2026

Successful Completion of $32 million Entitlement Offer

August 10, 2026

Application for quotation of securities - SPL

August 10, 2026

Entitlement Offer Investor Presentation

July 14, 2026

Fully Underwritten Entitlement Offer to Raise $32 Million

July 14, 2026

Quarterly Activities Report and Appendix 4C

July 14, 2026

DEP milestone triggers partner option fee

July 2, 2026

Positive DEP HER2-Lu preclinical data support Phase 1 entry

July 1, 2026

DEP radiopharmaceutical data supports patent application

July 1, 2026

FDA confirms path to DEP HER2 first-in-human study

April 21, 2026

Older news releases →

Decks in 2026